Biotech firm Aperion Biologics works to overcome rejection

20 April 2012

(April 2012) Officials with San Antonio-based Aperion Biologics Inc. expect to have approval to market their products in Europe, putting the company on a path to be cash-flow positive within the next two to three years.

Aperion is a clinical-stage medical device company that is seeking to address a need for alternatives for human tissue grafts in the sports medicine market. The company has a patented process for sterilizing and “humanizing” animal tissues so they can be used as graft material in humans without the fear of rejection.